WebApr 28, 2024 · The PROfound trial is a prospective, biomarker-selected, phase 3 trial involving men with metastatic castration-resistant prostate cancer who had disease … WebJul 22, 2024 · PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). METHODS ARCHES (ClinicalTrials.gov …
AFFIRM trial schema. mCRPC, metastatic castrate-resistant prostate ...
WebSep 2, 2024 · Furthermore, the incidence of metastatic prostate cancer seems to have increased in all races and age groups over the past decade. 1. Herein, we discuss the most recent advances in the management of metastatic prostate cancer and highlight recently approved agents and ongoing clinical trials. We will review the mechanism of action of … WebJan 23, 2010 · AFFIRM will enroll approximately 1,200 patients at sites in the United States and Canada, as well as in Europe, South America, Australia and South Africa. The study will test the efficacy and safety of MDV3100 in men with hormone-resistant prostate cancer that has progressed after chemotherapy. download microsoft visio 2016 trial version
Efficacy and safety of enzalutamide versus bicalutamide for …
WebApr 30, 2024 · A meta-analysis of the PREVAIL and AFFIRM trials, which studied the effects of enzalutamide therapy in men with chemotherapy-naive mCRPC (PREVAIL) or who had progressed despite docetaxel (AFFIRM ... WebProstate Cancer Clinical Trials. Please see below for our current listing of Prostate Cancer Multidisciplinary Clinic clinical trials. For a listing of all CCR prostate cancer … WebAFFIRM trial schema. mCRPC, metastatic castrate-resistant prostate cancer; PFS, progression-free survival; PSA, prostate-specific antigen; QOL, quality of life. Source publication... classical theory of lattice heat capacity